Metronidasool (Metronidazole) — sold most commonly under the brand name Flagyl — has been a cornerstone of antimicrobial therapy since the early 1960s. Few antibiotics match its particular combination of breadth and specificity: it is effective against a wide range of anaerobic bacteria and several parasitic protozoa, yet leaves aerobic organisms largely untouched.

Whether you encounter it as “metronidasool,” “metronidazol,” or “Flagyl,” you are looking at the same well-studied compound — a synthetic nitroimidazole with a pharmacological profile that has kept it on the World Health Organization’s List of Essential Medicines for decades. This guide covers everything clinically relevant about the drug, written for patients, caregivers, and healthcare students alike.

What Is Metronidasool (Metronidazole)?

Metronidasool (Metronidazole) is a synthetic antimicrobial agent belonging to the nitroimidazole class of drugs. It is active against anaerobic bacteria — organisms that survive in low-oxygen environments — as well as against certain parasitic protozoa including Giardia lamblia, Entamoeba histolytica, and Trichomonas vaginalis. Its dual antibacterial and antiprotozoal activity sets it apart from most antibiotics.

The compound was first synthesized in 1959 by scientists at Rhône-Poulenc in France, and the U.S. Food and Drug Administration approved its tablet form in July 1963 — making it one of the older drugs still in regular clinical use. That longevity is a reflection of how effective and cost-efficient it remains for its target organisms.

In everyday medical practice, doctors prescribe it for infections ranging from bacterial vaginosis and dental abscesses to intra-abdominal infections and protozoal bowel disease. The drug is available in several pharmaceutical forms: oral tablets (250 mg and 500 mg), extended-release tablets (750 mg), capsules (375 mg), intravenous solutions, topical cream (0.75% and 1%), topical gel, and vaginal gel.

How Does Metronidasool (Metronidazole) Work? Mechanism of Action

Metronidasool (Metronidazole) is a prodrug — it is chemically inactive until it enters a susceptible organism and undergoes intracellular reduction. Inside anaerobic bacteria and protozoa, an enzyme system involving ferredoxin or ferredoxin-like proteins transfers electrons to the drug’s nitro group, reducing it into toxic reactive intermediates.

These reactive metabolites then attack the organism’s DNA, disrupting its helical structure and inhibiting nucleic acid synthesis. The result is rapid bacterial cell death — what pharmacologists call a bactericidal effect. The killing is concentration-dependent, meaning higher drug concentrations produce faster and more complete eradication of the target organism.

“

“Metronidasool (Metronidazole) has rapid bactericidal effects against anaerobic bacteria with a killing rate proportional to drug concentration — a property that makes precise dosing particularly important in severe infections.”

— StatPearls / NCBI Bookshelf (National Institutes of Health)

Crucially, aerobic (oxygen-dependent) organisms lack the enzymatic machinery needed to reduce Metronidasool (Metronidazole) into its active form. This is why the drug does not harm the majority of aerobic gut bacteria and is ineffective against organisms like Escherichia coli in a typical uncomplicated urinary tract infection.

Resistance to Metronidasool (Metronidazole), while not common, does occur. It typically develops when bacteria reduce their expression of the nitroreductase enzymes needed to activate the drug. Incomplete or repeated courses of treatment are known to increase resistance risk, which is one reason clinicians emphasise completing the full prescribed course.

Medical Uses & Clinical Indications

Metronidasool (Metronidazole)’s clinical reach is broad. According to the Mayo Clinic and the NIH’s StatPearls database, it is an established first-line or adjunct therapy across a substantial range of bacterial and parasitic conditions. The following represents the most common and well-documented indications.

Bacterial Vaginosis (BV)

Bacterial vaginosis — an imbalance of the vaginal bacterial flora involving anaerobic overgrowth — is one of the most frequent reasons Metronidasool (Metronidazole) is prescribed. Oral regimens typically involve 500 mg twice daily for seven days, while a 0.75% vaginal gel applied once daily for five days is an alternative. Extended-release tablets (750 mg once daily for seven days) are also used in certain cases.

Trichomoniasis

Trichomoniasis is a sexually transmitted infection caused by the parasite Trichomonas vaginalis. Metronidasool (Metronidazole) remains the treatment of choice, commonly given as a single 2 g oral dose for both the patient and their partner, or alternatively as 500 mg twice daily for seven days. Because reinfection is common, partner treatment is considered essential.

Giardiasis and Intestinal Amebiasis

Giardia lamblia and Entamoeba histolytica are intestinal parasites that produce abdominal pain, cramping, and diarrhoea in infected individuals. Metronidasool (Metronidazole) is an established treatment for both. For amebic dysentery, typical dosing is 750 mg orally three times daily for five to ten days. Giardia treatment usually involves 250–500 mg three times daily for five to seven days.

Intra-Abdominal and Pelvic Infections

Metronidasool (Metronidazole) is frequently used in combination with other antibiotics to treat peritonitis, liver abscesses, pelvic inflammatory disease (PID), endometritis, and tubo-ovarian abscesses. Anaerobic organisms play a major role in these polymicrobial infections, making Metronidasool (Metronidazole) a valued component of combination regimens.

Clostridioides difficile (C. diff) Infections

Clostridioides difficile — the bacterium responsible for antibiotic-associated pseudomembranous colitis — has historically been treated with Metronidasool (Metronidazole) for mild-to-moderate cases, though clinical guidelines have evolved. Prescribers should refer to the most current institutional and national guidance, as vancomycin or fidaxomicin may be preferred in some settings.

H. pylori Eradication

Helicobacter pylori, the bacterium implicated in peptic ulcer disease and certain gastric cancers, is commonly treated with triple or quadruple therapy — regimens that include Metronidasool (Metronidazole) alongside other antibiotics (typically clarithromycin or amoxicillin) and a proton-pump inhibitor. The role of Metronidasool (Metronidazole) in H. pylori eradication depends on local resistance patterns, which your doctor will consider.

Dental and Oral Infections

Dental abscesses, periodontitis, and acute necrotising ulcerative gingivitis (ANUG) frequently involve anaerobic oral bacteria. Metronidazole, sometimes combined with amoxicillin, is a common adjunct to dental treatment in these situations. The drug achieves good tissue penetration into the oral cavity.

Rosacea (Topical Use)

Metronidazole gel and cream (0.75% and 1%) are prescribed for the inflammatory lesions of rosacea — a chronic skin condition causing facial redness and pustules. The mechanism here is thought to involve anti-inflammatory rather than strictly antimicrobial effects. Topical formulations are applied once or twice daily to affected areas.

Surgical Prophylaxis

Before colorectal surgeries and certain other abdominal procedures, Metronidasool (Metronidazole) is used prophylactically — administered around the time of surgery to prevent post-operative infections from the gut’s anaerobic flora. It is usually combined with a broad-spectrum antibiotic covering aerobic organisms as well.

Dosage, Forms & Administration

Dosage varies considerably depending on the indication, the severity of infection, patient age, and organ function. The figures below represent commonly cited regimens from clinical sources including the Mayo Clinic and Drugs.com. They are provided for educational context only — never adjust or initiate metronidazole treatment without the guidance of a prescribing clinician.

Available Pharmaceutical Forms

Metronidasool (Metronidazole) is manufactured in multiple forms to accommodate different routes of administration. Oral tablets (250 mg and 500 mg) are the most widely used for systemic infections. Extended-release 750 mg tablets are specifically indicated for bacterial vaginosis. Capsules of 375 mg exist as an alternative oral form. Intravenous infusion solutions allow direct delivery for hospitalised patients with severe infections or when oral intake is not possible. Topical options — cream, lotion, and gel at concentrations of 0.75% and 1% — are applied to the skin for rosacea. Vaginal gel is available for BV.

Storage is straightforward: tablets should be kept at room temperature, away from direct light and excessive heat. Storing medication in a car’s glove compartment — where temperatures can fluctuate significantly — is not recommended.

Side Effects, Warnings & Contraindications

Most people who take metronidazole tolerate it reasonably well, but the drug is not without side effects. Understanding them helps patients identify concerning symptoms early and communicate them to a healthcare provider.

Common Side Effects

The most characteristic and frequently reported side effect is a metallic or bitter taste in the mouth — a well-known nuisance that tends to resolve after the course ends. Gastrointestinal symptoms are also common: nausea, vomiting, diarrhoea, abdominal discomfort, and loss of appetite may occur, particularly at higher doses. Headache and mild dizziness are reported by some patients.

Serious Side Effects That Require Medical Attention

Peripheral neuropathy — damage to nerves outside the brain and spinal cord — can occur with prolonged or high-dose use. Symptoms include tingling, numbness, or weakness in the hands and feet. Central nervous system effects are less common but include seizures, confusion, and in rare cases metronidazole-induced encephalopathy (MIE), a reversible neurological condition.

Severe skin reactions — including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) — have been reported. These are rare but potentially life-threatening. If a patient develops a spreading rash or pus-filled skin lesions while on metronidazole, they should stop the drug immediately and seek medical care.

A drug reaction with eosinophilia and systemic symptoms (DRESS) — sometimes called multiorgan hypersensitivity — can affect the liver, kidneys, and heart. This is rare. Dark or reddish discolouration of the urine has also been documented in a small number of patients, attributed to the excretion of drug metabolites.

Metronidasool (Metronidazole) carries a black box warning from the FDA — the agency’s most serious caution — noting that the drug has shown carcinogenic activity in chronic studies in mice and rats. The clinical relevance of this finding to standard therapeutic use in humans is a matter of ongoing scientific discussion, and the drug remains widely prescribed based on its favourable benefit-risk profile in treating serious infections.

Contraindications

Metronidasool (Metronidazole) is contraindicated in patients with a known history of hypersensitivity to the drug or to other nitroimidazole derivatives. It should be avoided during the first trimester of pregnancy due to potential fetal toxicity concerns, and used with particular caution in patients with central nervous system disorders because of seizure risk. In patients with severe hepatic impairment, the dose should typically be reduced by 50%, as the liver is the primary site of drug metabolism.

Drug Interactions: What to Avoid

Metronidasool (Metronidazole) interacts with a meaningful number of other drugs and substances, and some of these interactions are clinically significant. Patients should always disclose all medications — prescription, over-the-counter, and herbal — when being assessed for Metronidasool (Metronidazole) therapy.

Alcohol — The Most Important Interaction

The interaction between Metronidasool (Metronidazole) and alcohol is well documented and clinically significant. Consuming alcohol during a metronidazole course — or within at least 48 hours of finishing it — can trigger a disulfiram-like reaction. This produces flushing, nausea, vomiting, rapid heartbeat, and general discomfort. The same mechanism applies to propylene glycol, found in certain intravenous drug formulations. Patients should be explicitly counselled to avoid alcohol during and immediately after treatment.

Warfarin (Blood Thinners)

Metronidasool (Metronidazole) inhibits certain liver enzymes (particularly CYP2C9) that metabolise warfarin. This can potentiate warfarin’s anticoagulant effect, raising the risk of bleeding. Patients on warfarin therapy who require metronidazole need closer INR monitoring during the course.

Lithium

Concurrent use of metronidazole can elevate serum lithium levels, potentially causing lithium toxicity — a serious condition with neurological and cardiac manifestations. Monitoring of lithium levels is advisable when both drugs are prescribed together.

Phenytoin and Phenobarbital

Metronidasool (Metronidazole) may increase phenytoin levels by inhibiting its hepatic metabolism, warranting monitoring. Conversely, phenobarbital — an inducer of liver enzymes — can significantly reduce metronidazole’s serum concentration by accelerating its breakdown.

Cimetidine

Cimetidine, a histamine-2 blocker sometimes used for stomach acid problems, reduces the hepatic metabolism of Metronidasool (Metronidazole). This can increase metronidazole’s serum concentration and raise the potential for side effects. Healthcare providers generally take this interaction into account when prescribing both drugs simultaneously.

Use in Pregnancy & Breastfeeding

The use of metronidazole during pregnancy warrants careful consideration. During the first trimester, the drug is generally contraindicated because of concerns about potential fetal toxicity during this critical developmental window. The prescribing decision must weigh the severity of the infection against the risks involved, and this is very much a clinical judgement made by a qualified physician.

During the second and third trimesters, metronidazole may be used when the clinical benefit is judged to outweigh the risks. Bacterial vaginosis in pregnancy, for example, has been associated with complications including preterm birth, and treating it effectively carries real clinical importance.

Metronidasool (Metronidazole) is excreted in breast milk. Women who are breastfeeding should generally not use the drug, given the potential for adverse effects on the newborn. If treatment is essential, interrupting breastfeeding for the duration of the course — and for a period after the last dose — may be recommended. This is a decision to be made with a healthcare provider’s guidance.

Special Populations: Older Adults, Liver & Kidney Disease

In older adults, the kidneys and liver typically process drugs more slowly. Because metronidazole is metabolised primarily by the liver and excreted by the kidneys, reduced organ function can allow the drug to accumulate to higher levels in the body over time, increasing side-effect risk. Prescribers may start with a lower dose or less frequent dosing schedule in elderly patients.

Patients with severe hepatic impairment should have their systemic dose reduced by approximately 50%. No specific dose adjustment is routinely recommended for topical metronidazole use in patients with liver or kidney problems, though clinical judgement applies.